Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Crism TherapeuticsSTU:A7L 37 Days Payable is 290.19 as of Dec. 2025, which is 89% below its 10-year median of 2,526.48. GuruFocus rates STU:A7L with a GF Score™ of 37/100. The stock has 3 warning signs investors should review. Among 702 Biotechnology companies, Crism Therapeutics ranks better than 75.78% on this metric.
The historical rank and industry rank for Crism Therapeutics's Days Payable or its related term are showing as below:
STU:A7L'
s Days Payable Range Over the Past 10 Years
Min: 406.37 Med: 2526.48 Max: 16607.5
Current: 406.37
During the past 13 years, Crism Therapeutics's highest Days Payable was 16607.50. The lowest was 406.37. And the median was 2526.48.
STU:A7L's Days Payable is ranked better than 75.78% of 702
companies
in the Biotechnology industry
Industry Median: 113.1
vs STU:A7L: 406.37
Crism Therapeutics's Days Payable
declined
from Dec. 2024 (3,887.25) to Dec. 2025 (290.19).
It may suggest that Crism Therapeuticsaccelerated paying its suppliers.
Crism Therapeutics Days Payable Related Terms
Crism Therapeutics Days Payable Historical Data
* Premium members only.
The historical data trend for Crism Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:A7L vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Crism Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crism Therapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Crism Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Crism Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Crism Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crism Therapeutics (STU:A7L) has a Days Payable of 290.19 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Crism Therapeutics and its competitors. This is 89% below median its historical median of 2,526.48. Over the past decade, Crism Therapeutics' Days Payable has ranged from 406.37 to 16,607.50. According to the industry distribution chart, Crism Therapeutics ranks #170 out of 702 companies in the Biotechnology industry, placing it in the top 24.2%.
Is Crism Therapeutics' Days Payable too high?
Crism Therapeutics' current Days Payable of 290.19 is 89% below median its 10-year median of 2,526.48. Over the past 10 years, this metric has ranged from a low of 406.37 to a high of 16,607.50. The Biotechnology industry median Days Payable is 113.10. Crism Therapeutics' value of 290.19 is 156.6% above this industry median. Based on the distribution chart, Crism Therapeutics ranks #170 out of 702 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Crism Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Crism Therapeutics' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Crism Therapeutics ranks #170 out of 702 companies for Days Payable. This places Crism Therapeutics in the top 24% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.10. Crism Therapeutics' value of 290.19 is 156.6% above this benchmark. Historically, Crism Therapeutics' own Days Payable has ranged from 406.37 to 16,607.50 over the past decade. While the company's 10-year median is 2,526.48 vs. the industry median of 113.10, Crism Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Crism Therapeutics's current Days Payable of 290.19 is 156.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Crism Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Crism Therapeutics's current Days Payable is 290.19, which is 89% below median its own 10-year median of 2,526.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crism Therapeutics stock overvalued right now?
Crism Therapeutics (STU:A7L) has a current Days Payable of 290.19. The current Days Payable is 290.19, which is 89% below median its 10-year median of 2,526.48 and 156.6% above the Biotechnology industry median of 113.10. Crism Therapeutics' overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Crism Therapeutics (STU:A7L), the current Days Payable is 290.19 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Crism Therapeutics Corp has developed a drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. Its product ChemoSeed which is in its clinical trial phase, can be implanted directly into the tumour or the resection margin following the removal of a tumour. The company also provides consultancy and formulation services to its clients assisting them with pharmaceutical formulation and development.
37GF Score
Get the complete analysis for STU:A7L
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:A7L has been successfully added to your 
